RayzeBio Shares Soar Premarket on Takeover by Bristol Myers
26 12월 2023 - 10:04PM
Dow Jones News
By Colin Kellaher
RayzeBio shares nearly doubled in premarket trading Tuesday
after the clinical-stage radiopharmaceutical therapeutics company
agreed to be acquired by Bristol Myers Squibb at a rich
premium.
Bristol Myers will pay $62.50 a share for RayzeBio, a 104%
premium to Friday's closing price of $30.57.
The deal carries an equity value of around $4.1 billion and a
total value of $3.6 billion net of RayzeBio's cash on hand.
RayzeBio shares were recently up 99% to $60.90 in premarket
trading.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
December 26, 2023 07:49 ET (12:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
RayzeBio (NASDAQ:RYZB)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
RayzeBio (NASDAQ:RYZB)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
